Skip to main
PMN
PMN logo

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. demonstrates a positive outlook due to its promising clinical results for PMN310, which has shown favorable safety profiles and pharmacokinetics in Phase 1a testing, supporting its progression towards further clinical development. Additionally, the advancements in PMN267 highlight its selective targeting capabilities, which could lead to significant disease-modifying activity and safety enhancements across various neurodegenerative diseases. The absence of adverse reactions associated with competing therapies and the robust in vitro validation underpin the company's potential for growth and the likelihood of achieving meaningful clinical milestones.

Bears say

ProMIS Neurosciences has reported a significant net loss of $11.6 million, or $0.24 per share, for the third quarter of 2025, reflecting ongoing financial struggles with no history of profitability. The company faces potential challenges that may hinder its operational success, including the risks of future partnerships, competition that may slow market uptake, and concerns regarding near-term dilution. Additionally, emerging scientific evidence suggests that the company’s focus on targeting toxic Aβ oligomers could be undermined by previously failed therapies, raising doubts about the efficacy of its proposed solutions in treating neurodegenerative diseases.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.